养血清脑颗粒治疗急性期脑出血的临床研究

目的：通过养血清脑颗粒与单纯西医治疗急性期脑出血的临床随机对照观察,评价养血清脑颗粒治疗急性期脑出血的疗效及安全性。方法：108例急性期脑出血患者分为观察组和对照组各54例,对照组采用西医常规治疗,观察组在西医常规治疗基础上加用养血清脑颗粒,4g,日3次口服。治疗14天、30天进行疗效评定。观察急性期死亡率、再出血比率,评价神经功能缺损程度（CNIS）和日常生活能力（ADL）。结果：（1）观察组14天内死亡10例（18.5%）,对照组死亡11例（20.4%）,组间比较χ2=0.05,P=0.81;（2）观察组和对照组再出血发生率分别是9.26%（5/54）和7.41%（4/54）,χ2=0.12,P=0.73;（3）两组治疗前CNIS评分无统计学差异,治疗后14天和30天CNIS评分均下降,以观察组下降更明显,观察组与对照组治疗前后比较分别P〈0.01和P〈0.05;（4）30天存活患者ADL分级观察组优于对照组,χ2=10.310,P=0.036。结论：养血清脑颗粒治疗急性期脑出血可促进血肿吸收,不增加再出血的风险,更利于神经功能和日常生活能力的康复。

Clinical Study of Yangxueqingnao Granule on Treating Acute-stage Cerebral Hemorrhage

Objective：To compare the efficacy and safety of Yangxueqingnao granule union western routine medicine and western routine medicine in treating acute-stage cerebral hemorrhage.Methods：Divides into two groups stochastically 108 example acute-stage cerebral hemorrhage patient,the control group only takes western routine medicine,the observation group takes western routine medicine union Yangxueqingnao granule to take orally 4 gram ter in die.Observe curative effect,mortality rate during acute period and recurrent hemorrhage rate.CNIS and ADL Scale of 2 groups were assessed and compared before treatment and 14 days months,30 days after treatment.Results：The mortality rate in two groups were 18.5%（10/54 cases）and 20.4%（11/54 cases）,respectively.The recurrent hemorrhage rate were 9.26%（5/54 cases） and 7.41%（4/54 cases）,respectively.The CNIS of two groups comparisons have no significance difference before treatment.The CNIS of two groups all decline 14 days and 30 days after treatment.The observation group obviously change of CNIS（P0.01） than the control group（P0.05）.The survive ADL is lower than the control group.Conclusion： Yangxueqingnao granule promote hematoma absorb and not increase recurrent hemorrhage rate.Therapeutic effect of Yangxueqingnao granule union western routine medicine is better than that of routine medicine in treating acute-stage cerebral hemorrhage.